Profile data is unavailable for this security.
About the company
Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases.
- Revenue in CAD (TTM)0.00
- Net income in CAD-40.73m
- Incorporated2001
- Employees--
- LocationSernova Corp700 Collip Circle, Ste 114LONDON N6G 4X8CanadaCAN
- Phone+1 (519) 858-5126
- Fax+1 (519) 858-5126
- Websitehttps://www.sernova.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Theratechnologies Inc | 106.88m | -24.62m | 82.30m | 89.00 | -- | -- | -- | 0.7701 | -0.8478 | -0.8478 | 3.28 | -0.7322 | 1.03 | 1.89 | 7.81 | -- | -23.78 | -26.32 | -128.23 | -55.43 | 74.10 | 65.90 | -23.04 | -38.26 | 1.03 | -0.919 | 1.71 | -- | 2.13 | 12.58 | 49.28 | -- | -37.83 | -- |
| Biosyent Inc | 31.59m | 6.46m | 102.05m | 0.00 | 16.26 | 2.92 | 14.76 | 3.23 | 0.5319 | 0.5319 | 2.60 | 2.96 | 0.7704 | 1.15 | 10.12 | -- | 15.75 | 14.77 | 18.26 | 16.92 | 81.03 | 79.74 | 20.45 | 19.99 | 5.42 | -- | 0.0339 | 9.26 | 13.12 | 7.97 | 18.35 | 2.52 | -2.67 | -- |
| Arch Biopartners Inc | 1.85m | -1.95m | 111.25m | -- | -- | -- | -- | 60.23 | -0.0312 | -0.0312 | 0.0296 | -0.091 | 2.73 | -- | 4.38 | -- | -288.23 | -214.82 | -- | -- | -- | -- | -105.69 | -180.45 | -- | -3.94 | -- | -- | 105.63 | -- | -136.30 | -- | -- | -- |
| Spectral Medical Inc | 1.60m | -15.51m | 119.82m | 29.00 | -- | -- | -- | 74.98 | -0.0557 | -0.0562 | 0.0057 | -0.0594 | 0.1857 | 2.65 | 2.57 | 55,103.45 | -180.25 | -109.65 | -1,031.80 | -175.35 | 41.36 | 63.74 | -970.46 | -445.72 | 0.367 | -3.71 | -- | -- | -4.14 | -16.08 | -104.12 | -- | 31.53 | -- |
| Oncolytics Biotech Inc | 0.00 | -27.75m | 120.67m | 29.00 | -- | 4.32 | -- | -- | -0.4144 | -0.4144 | 0.00 | 0.3704 | 0.00 | -- | -- | -- | -72.88 | -81.99 | -81.66 | -97.25 | -- | -- | -- | -- | -- | -- | 0.0151 | -- | -- | -- | -11.75 | -- | -40.52 | -- |
| Sernova Corp | 0.00 | -40.73m | 121.36m | -- | -- | 31.65 | -- | -- | -0.1343 | -0.1343 | 0.00 | 0.0126 | 0.00 | -- | -- | -- | -124.29 | -74.84 | -180.95 | -85.03 | -- | -- | -- | -- | -- | -- | 0.142 | -- | -- | -- | -59.69 | -- | -2.91 | -- |
| Eupraxia Pharmaceuticals Inc | 0.00 | -38.62m | 140.35m | 29.00 | -- | 35.44 | -- | -- | -1.60 | -1.60 | 0.00 | 0.1112 | 0.00 | -- | -- | 0.00 | -147.08 | -127.84 | -307.19 | -935.99 | -- | -- | -- | -- | -- | -25.65 | 0.9213 | -- | -- | -- | -52.63 | -- | -7.69 | -- |
| Zentek Ltd | 33.61k | -11.98m | 143.16m | 27.00 | -- | 6.37 | -- | 4,259.56 | -0.1197 | -0.1197 | 0.0003 | 0.2228 | 0.0013 | 0.0796 | 0.0876 | 1,244.82 | -44.53 | -41.94 | -48.53 | -44.46 | -573.70 | -- | -35,636.60 | -12,771.31 | 4.27 | -- | 0.0538 | -- | -79.01 | -- | 54.52 | -- | 39.27 | -- |
| NervGen Pharma Corp | 0.00 | -22.38m | 162.93m | 10.00 | -- | -- | -- | -- | -0.3772 | -0.3772 | 0.00 | -0.0337 | 0.00 | -- | -- | -- | -120.62 | -121.15 | -380.82 | -180.20 | -- | -- | -- | -- | -- | -3.86 | -- | -- | -- | -- | -8.01 | -- | 2.20 | -- |
| Holder | Shares | % Held |
|---|---|---|
| CATAM Asset Management AGas of 29 Feb 2024 | 150.00k | 0.05% |
| Next Edge Capital Corp.as of 31 Dec 2023 | 115.50k | 0.04% |
